Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Longevity of Immunity Following Covid-19 Vaccination: A Comprehensive Review of the Currently Approved Vaccines Publisher Pubmed



Jamshidi E1 ; Asgary A2 ; Shafiekhani P3 ; Khajeamiri Y4 ; Mohamed K5, 6 ; Esmaily H4 ; Jamal Rahi S7 ; Mansouri N8, 9, 10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Biotechnology, College of Sciences, University of Tehran, Tehran, Iran
  3. 3. USERN office, Functional Neurosurgery Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Manama, Bahrain
  7. 7. Laboratory of the Physics of Biological Systems, Institute of Physics, Ecole polytechnique federale de Lausanne (EPFL), Lausanne, Switzerland
  8. 8. Division of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland
  9. 9. Research Group on Artificial Intelligence in Pulmonary Medicine, Division of Pulmonary Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  10. 10. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole polytechnique federale de Lausanne (EPFL), Lausanne, Switzerland

Source: Human Vaccines and Immunotherapeutics Published:2022


Abstract

It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively. © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.